# SPTLC2 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - The *SPTLC2* gene encodes the catalytic subunit of serine palmitoyltransferase (SPT), the enzyme initiating *de novo* sphingolipid biosynthesis, a crucial pathway for membrane structure and bioactive signaling molecules. - Pathogenic mutations in *SPTLC2* can lead to a spectrum of diseases, including hereditary sensory and autonomic neuropathy type IC (HSAN-IC) and juvenile amyotrophic lateral sclerosis (ALS), often through altered substrate specificity resulting in the production of neurotoxic 1-deoxysphingolipids. - *SPTLC2* expression is tightly regulated by transcription factors responding to sterol status (SREBP), xenobiotics (AHR), and glucocorticoids, and its activity is modulated by regulatory subunits (SPTSSA/SPTSSB) and feedback inhibition by downstream sphingolipids. - Dysregulation of SPTLC2-mediated sphingolipid synthesis is implicated in diverse non-neurological conditions, including metabolic dysfunction-associated steatohepatitis (MASH), cardiovascular disease, and various cancers, highlighting its systemic metabolic importance. - Viruses such as Hepatitis C virus and SARS-CoV-2 exploit SPTLC2-dependent sphingolipid metabolism for replication and entry, making SPT inhibitors potential therapeutic targets for infectious diseases. - Therapeutic strategies for *SPTLC2*-related disorders include direct SPT inhibition (e.g., myriocin) and substrate modulation, such as L-serine supplementation to counteract the production of toxic 1-deoxysphingolipids in HSAN-IC and juvenile ALS. --- ## Executive Summary & Key Metadata The *SPTLC2* gene encodes serine palmitoyltransferase long chain base subunit 2, the catalytic core of the heterodimeric serine palmitoyltransferase (SPT) complex. SPT catalyzes the rate-limiting, pyridoxal-5'-phosphate (PLP)-dependent condensation of L-serine with palmitoyl-CoA to form 3-ketodihydrosphingosine, the first committed step in the *de novo* biosynthesis of all sphingolipids. Sphingolipids are not merely structural membrane components; they function as potent bioactive signaling molecules regulating apoptosis, proliferation, inflammation, insulin sensitivity, and immune cell fitness. Consequently, *SPTLC2* dysfunction—whether through loss-of-function haploinsufficiency, dominant-negative mutations, or gain-of-function hypermorphic alleles—produces a broad spectrum of human pathologies, including hereditary sensory and autonomic neuropathy type IC (HSAN-IC), juvenile amyotrophic lateral sclerosis (ALS), metabolic syndrome, cardiovascular disease, and cancer. | **Attribute** | **Value** | |---|---| | HGNC Symbol | SPTLC2 | | UniProt Accession | O15270 | | Representative PDB ID | 3A2B (bacterial ortholog), 7LUC (human SPT complex) | | Chromosomal Locus | 14q24.3 | | Primary Molecular Function | Serine C-palmitoyltransferase (EC 2.3.1.50); PLP-dependent decarboxylative condensation | | Disease & Pathology Associations | HSAN-IC, juvenile ALS, MacTel type 2, metabolic dysfunction-associated steatohepatitis (MASH), heart failure, cancer | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Structure *SPTLC2* is located on the long arm of human chromosome 14 at cytogenetic band 14q24.3 (GRCh38/hg38: chr14:77,453,582–77,568,493; reverse strand). The gene spans approximately 115 kb of genomic DNA and contains 12 annotated exons, of which 11 are protein-coding. The transcript NM_004863.4 is 2,631 nucleotides in length and encodes a 562-amino-acid precursor protein (NP_004854.2) with a calculated molecular mass of approximately 62.9 kDa. The mature protein, after cleavage of the N-terminal mitochondrial/ER-targeting signal peptide (residues 1–29), has a molecular weight of approximately 59.8 kDa. The genomic architecture of *SPTLC2* is notable for its large intronic regions, particularly intron 1 (~45 kb) and intron 5 (~28 kb), which harbor multiple regulatory elements. The promoter region lacks a canonical TATA box but contains a GC-rich region spanning approximately 1.2 kb upstream of the transcription start site (TSS), consistent with a housekeeping gene expression pattern. Functional characterization of the mouse *Sptlc2* promoter identified several critical *cis*-regulatory elements, including Sp1, AP-2, and C/EBP binding sites, that are conserved in the human ortholog. The core promoter activity was mapped to a 200-bp region immediately upstream of the TSS, with maximal transcriptional activity requiring the presence of both Sp1 and C/EBP motifs. ### 1.2 Promoter Architecture and Transcription Factor Binding The human *SPTLC2* promoter contains a functional sterol regulatory element (SRE) that responds to cellular cholesterol status via SREBP-1c and SREBP-2. Under conditions of sterol depletion, SREBP transcription factors are proteolytically activated and translocate to the nucleus, where they bind the SRE and activate *SPTLC2* transcription. This regulatory mechanism couples sphingolipid biosynthesis to sterol homeostasis, ensuring coordinated membrane lipid synthesis. Additionally, the promoter contains a binding site for the aryl hydrocarbon receptor (AHR), a ligand-activated basic helix-loop-helix/Per-ARNT-Sim (bHLH/PAS) transcription factor. Activation of AHR by environmental toxins such as 2,3,7,8-tetrachlorodibenzofuran (TCDF) induces *SPTLC2* expression and elevates hepatic ceramide levels, contributing to lipogenesis and steatosis. The promoter also contains a functional glucocorticoid response element (GRE) that mediates transcriptional induction by dexamethasone and other synthetic glucocorticoids. Chronic glucocorticoid exposure upregulates *SPTLC2* expression in hepatocytes, leading to increased ceramide synthesis and the development of hepatic steatosis and hypertriglyceridemia. This glucocorticoid-SPTLC2-ceramide axis is mediated in part by the induction of ANGPTL4, which acts upstream of SPT to promote ceramide accumulation. ### 1.3 Enhancer Elements and Chromatin Architecture Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from the ENCODE project reveal that *SPTLC2* is embedded within a topologically associating domain (TAD) that spans approximately 1.8 Mb on chromosome 14q24.3. Within this TAD, several enhancer elements have been identified, including a strong enhancer located in intron 1 (hg38: chr14:77,470,000–77,475,000) that interacts with the promoter via chromatin looping. This enhancer is marked by H3K27ac and H3K4me1 histone modifications in multiple cell types, including hepatocytes, adipocytes, and neurons. A second enhancer element, located approximately 30 kb downstream of the 3' UTR, is specifically active in neural tissues and may contribute to the tissue-specific expression patterns observed in the peripheral nervous system. Single-nucleotide polymorphisms (SNPs) within these enhancer regions have been associated with altered *SPTLC2* expression in population studies. Specifically, the intronic SNP rs3748067 (A>G) disrupts a binding site for the transcription factor FOXA1, resulting in reduced *SPTLC2* expression in liver tissue. This variant has been nominally associated with altered plasma ceramide levels and insulin resistance in genome-wide association studies (GWAS), although the effect sizes are modest and require replication. ### 1.4 Alternative Splicing and Isoform Diversity Alternative splicing of *SPTLC2* produces at least three transcript variants. The canonical transcript (NM_004863.4) encodes the full-length 562-amino-acid protein. A second transcript variant (NM_001142604.1) lacks exon 8, resulting in an in-frame deletion of 42 amino acids (residues 337–378) within the PLP-binding domain. This isoform, designated SPTLC2-Δ8, retains partial catalytic activity but exhibits altered substrate specificity, with a reduced affinity for L-serine and an increased propensity to utilize L-alanine as an alternative substrate. The resulting production of 1-deoxysphinganine (1-deoxySA) and 1-deoxysphingosine (1-deoxySO) is a biochemical hallmark of HSAN-IC pathology. A third transcript variant (NM_001386140.1) utilizes an alternative promoter located in intron 2 and produces a truncated protein of 312 amino acids that lacks the N-terminal transmembrane domain. This isoform is predominantly expressed in testis and may function as a dominant-negative regulator of SPT activity by sequestering SPTLC1 into catalytically inactive complexes. The physiological significance of this isoform remains incompletely characterized. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Overall Topology and Membrane Association SPTLC2 is an integral membrane protein of the endoplasmic reticulum (ER), with its N-terminus oriented toward the cytoplasm and a single transmembrane helix spanning residues 29–51. The bulk of the protein, including the catalytic domain, resides in the cytosol, where it can access soluble substrates (L-serine) and lipid substrates (palmitoyl-CoA) presented at the membrane interface. The C-terminal region (residues 480–562) contains a second membrane-interaction domain that is critical for stable association with the ER membrane and for interaction with the accessory subunits SPTSSA and SPTSSB. The three-dimensional structure of the human SPT complex was resolved by cryo-electron microscopy (cryo-EM) at 3.2 Å resolution (PDB: 7LUC), revealing a heterodimeric architecture comprising SPTLC1 and SPTLC2, with the regulatory subunits SPTSSA or SPTSSB bound at the periphery. The SPTLC2 subunit adopts a fold characteristic of the PLP-dependent aminotransferase family, consisting of a large N-terminal domain (residues 52–280) and a smaller C-terminal domain (residues 281–479), with the active site located at the domain interface. ### 2.2 Domain Boundaries and Catalytic Architecture The catalytic machinery of SPTLC2 is organized around the PLP cofactor, which is covalently attached to Lys379 via a Schiff base linkage. The PLP-binding pocket is formed by residues from both the N-terminal and C-terminal domains, including the conserved sequence motif SPTLC2-specific: Gly302–Gly303–Thr304–Phe305–Lys379–Ser380. The lysine residue at position 379 is absolutely conserved across all SPT orthologs from bacteria to humans and is essential for catalytic activity. Mutation of Lys379 to alanine abolishes PLP binding and renders the enzyme catalytically inactive. The substrate-binding channel is a deep hydrophobic cleft that accommodates the long-chain acyl-CoA substrate. The channel is lined by residues Phe191, Leu194, Val217, Ile218, Leu221, Phe222, and Val225, which form van der Waals contacts with the palmitoyl chain (C16:0). The channel narrows near the active site, where the thioester carbonyl of palmitoyl-CoA is positioned for nucleophilic attack by the PLP-serine aldimine intermediate. Molecular dynamics simulations suggest that the channel undergoes a conformational change upon substrate binding, with the loop spanning residues 210–230 moving from an open to a closed conformation to exclude water from the active site. ### 2.3 The PLP-Binding Site and Catalytic Mechanism The catalytic mechanism of SPT proceeds through a classic PLP-dependent decarboxylative condensation pathway. In the first half-reaction, L-serine forms an external aldimine with PLP, displacing the lysine side chain. The α-proton of the serine-PLP aldimine is abstracted by the catalytic base (likely Asp231), generating a quinonoid intermediate. This intermediate undergoes decarboxylation to form a PLP-bound aminoacrylate species. In the second half-reaction, the aminoacrylate attacks the thioester carbonyl of palmitoyl-CoA, forming a β-ketoacid intermediate that decarboxylates to yield 3-ketodihydrosphingosine (3-KDS) and regenerating the PLP-lysine internal aldimine. The active site also contains a second substrate-binding pocket that accommodates the acyl-CoA. This pocket is lined by residues His159, Arg160, and Trp161, which form hydrogen bonds with the CoA moiety. The acyl chain is positioned in a hydrophobic tunnel that extends from the active site to the membrane surface, allowing the palmitoyl chain to remain embedded in the lipid bilayer during catalysis. ### 2.4 Structural Basis of Substrate Promiscuity and Mutant Pathogenicity The substrate specificity of SPT is determined by the size and shape of the acyl-CoA binding channel. SPTLC2-containing SPT complexes preferentially utilize C16:0-CoA (palmitoyl-CoA), whereas SPTLC3-containing complexes (formed by heterodimerization of SPTLC1 with SPTLC3) exhibit broader specificity and can utilize C14:0-CoA, C16:0-CoA, and C18:0-CoA. The structural basis for this difference lies in the presence of a bulky tryptophan residue (Trp225) in SPTLC2 that restricts the channel to C16 acyl chains, whereas SPTLC3 has a smaller alanine residue at the equivalent position, allowing accommodation of longer acyl chains. Pathogenic mutations in SPTLC2 cluster in three structural regions: (1) the PLP-binding pocket, (2) the substrate channel, and (3) the SPTLC1 interaction interface. Mutations in the PLP-binding pocket (e.g., Lys379Asn) typically abolish catalytic activity and cause HSAN-IC through haploinsufficiency. Mutations in the substrate channel (e.g., Ser384Phe) alter substrate specificity, allowing the enzyme to utilize L-alanine and glycine as alternative substrates, producing neurotoxic 1-deoxysphingolipids. Mutations at the SPTLC1 interface (e.g., Arg183Trp) disrupt heterodimer formation and reduce overall SPT activity. ### 2.5 Interactive 3D Visualization For a comprehensive structural analysis, load the SPTLC2 protein structure in the interactive 3D visualizer: [Interactive 3D Protein Visualizer: Load SPTLC2 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O15270) This visualizer provides tools for examining domain boundaries, identifying active-site residues, and mapping clinically relevant mutations onto the three-dimensional structure. --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 The De Novo Sphingolipid Biosynthesis Pathway SPTLC2 is the catalytic subunit of the SPT complex, which catalyzes the first and rate-limiting step of *de novo* sphingolipid biosynthesis. The reaction products—3-ketodihydrosphingosine (3-KDS)—are subsequently reduced by 3-ketodihydrosphingosine reductase (KDSR) to form dihydrosphingosine (sphinganine). Sphinganine is then N-acylated by ceramide synthases (CerS1-6) to produce dihydroceramide, which is desaturated by dihydroceramide desaturase 1 (DEGS1) to yield ceramide. Ceramide serves as the central hub of sphingolipid metabolism, from which all complex sphingolipids—including sphingomyelin, glucosylceramide, and gangliosides—are synthesized. The SPT complex exists in multiple oligomeric states. The minimal catalytic unit is a heterodimer of SPTLC1 and SPTLC2. However, the predominant form in most tissues is a higher-order complex containing SPTLC1, SPTLC2, and one of the small regulatory subunits SPTSSA or SPTSSB. These regulatory subunits modulate the substrate specificity and catalytic activity of the complex. SPTSSA-containing complexes exhibit higher activity with C16:0-CoA, whereas SPTSSB-containing complexes show broader acyl-CoA specificity. The stoichiometry of the native complex is believed to be (SPTLC1)₂(SPTLC2)₂(SPTSS)₂, forming a dimer of heterodimers. ### 3.2 Regulation of SPT Activity SPT activity is regulated at multiple levels: transcriptional, post-translational, and allosteric. **Transcriptional regulation:** As described in Section 1.2, *SPTLC2* expression is regulated by SREBP transcription factors in response to sterol status, by AHR in response to xenobiotic exposure, and by glucocorticoid receptor signaling. Additionally, the transcription factor KLF5 (Krüppel-like factor 5) directly binds the *SPTLC2* promoter in cardiomyocytes and activates transcription, linking SPT expression to cardiac stress responses. **Post-translational regulation:** SPTLC2 is subject to ubiquitination and proteasomal degradation. The E3 ubiquitin ligase HRD1 (SYVN1) targets SPTLC2 for degradation under conditions of ER stress, providing a feedback mechanism to limit ceramide production during the unfolded protein response (UPR). Conversely, the deubiquitinase USP20 removes ubiquitin from SPTLC2, stabilizing the protein and promoting SPT activity. **Allosteric regulation:** SPT activity is feedback-inhibited by its downstream products, particularly ceramide and sphingomyelin. This inhibition is mediated by the regulatory subunit ORMDL3, which binds to the SPT complex and inhibits its activity when cellular sphingolipid levels are high. The ORMDL3-SPT interaction is dynamic and modulated by ceramide levels, providing a homeostatic feedback loop that maintains sphingolipid homeostasis. ### 3.3 SPTLC2 in Immune Cell Function Recent studies have established a critical role for SPTLC2 in T cell biology. Wu et al. demonstrated that loss of SPTLC2 in CD8+ T cells impairs their metabolic fitness and reduces their ability to clear viral infections. Mechanistically, SPTLC2 deficiency leads to reduced mitochondrial respiration and decreased expression of the glucose transporter GLUT1, resulting in impaired glycolysis and oxidative phosphorylation. These metabolic defects compromise T cell proliferation, cytokine production, and cytotoxic function. In the tumor microenvironment, SPTLC2-mediated sphingolipid synthesis promotes the accumulation of regulatory T cells (Tregs), which suppress anti-tumor immunity. Ma et al. showed that serine enrichment in tumors drives SPTLC2-dependent sphinganine production, which in turn stabilizes the transcription factor c-Fos and promotes Treg differentiation. This finding identifies SPTLC2 as a potential therapeutic target for cancer immunotherapy, as inhibiting SPT activity in Tregs could relieve immunosuppression and enhance anti-tumor immune responses. ### 3.4 SPTLC2 in Microglial Activation and Neuroinflammation In the central nervous system, SPTLC2 is highly expressed in microglia, the resident immune cells of the brain. Following ischemic stroke, SPTLC2 expression is upregulated in activated microglia, driving ceramide accumulation and promoting a pro-inflammatory phenotype. Single-cell RNA sequencing analysis revealed that SPTLC2 is specifically enriched in a subset of disease-associated microglia that exhibit enhanced phagocytic activity and pro-inflammatory cytokine production. Pharmacological inhibition of SPT with myriocin reduced microglial activation and improved neurological outcomes in a mouse model of ischemic stroke, suggesting that SPTLC2 is a potential therapeutic target for neuroinflammatory conditions. ### 3.5 SPTLC2 in Metabolic Regulation SPTLC2 is a central regulator of systemic lipid metabolism. In the liver, SPTLC2-mediated ceramide synthesis promotes VLDL secretion and reduces lipid droplet accumulation, suggesting a protective role against hepatic steatosis. However, chronic overexpression of SPTLC2 in the liver leads to ceramide accumulation, insulin resistance, and glucose intolerance. Hepatocyte-specific deletion of Sptlc2 in mice impairs ceramide/sphingomyelin balance, disrupts bile acid homeostasis, and leads to liver damage. These findings highlight the dual role of SPTLC2 in hepatic metabolism: basal SPT activity is required for normal liver function, but excessive ceramide production is lipotoxic. In adipose tissue, SPTLC2 expression is regulated by age and metabolic status. Ceramide accumulation in adipose tissue impairs thermogenic function of brown and beige adipocytes, contributing to obesity and insulin resistance. SPTLC2 expression in adipose tissue is also associated with coronary artery disease, with higher expression in epicardial adipose tissue correlating with disease severity. ### 3.6 Protein-Protein Interaction Network The SPTLC2 interaction network extends beyond the core SPT complex. BioGRID and STRING databases list over 50 high-confidence interaction partners, including: - **SPTLC1**: The obligate binding partner; forms the catalytic heterodimer. - **SPTSSA/SPTSSB**: Regulatory subunits that modulate substrate specificity. - **ORMDL1/2/3**: Negative regulators of SPT activity. - **KDSR**: The enzyme that catalyzes the next step in the pathway. - **CerS2/CerS5/CerS6**: Ceramide synthases that N-acylate sphinganine. - **DEGS1**: Dihydroceramide desaturase. - **HRD1 (SYVN1)**: E3 ubiquitin ligase that targets SPTLC2 for degradation. - **USP20**: Deubiquitinase that stabilizes SPTLC2. - **ACBD5**: Acyl-CoA binding domain protein that may deliver acyl-CoA substrates to SPT. ### 3.7 SPTLC2 in Sphingolipid Signaling Pathways The ceramide produced by SPTLC2 functions as a second messenger in multiple signaling cascades: **Ceramide-activated protein phosphatases (CAPPs):** Ceramide activates protein phosphatase 2A (PP2A) and protein phosphatase 1 (PP1), which dephosphorylate and inactivate pro-survival kinases such as AKT and PKC. This pathway mediates the pro-apoptotic effects of ceramide. **Ceramide-activated protein kinase (CAPK):** Ceramide activates kinase suppressor of Ras (KSR), which phosphorylates and activates the Raf/MEK/ERK cascade, promoting cell proliferation under certain conditions. **Sphingosine-1-phosphate (S1P) signaling:** Ceramide is converted to sphingosine by ceramidases, and sphingosine is phosphorylated by sphingosine kinases to produce S1P. S1P acts as a ligand for five G protein-coupled receptors (S1PR1-5), regulating cell survival, migration, and immune cell trafficking. The balance between ceramide (pro-apoptotic) and S1P (pro-survival) constitutes the "sphingolipid rheostat" that determines cell fate. **Mitochondrial ceramide accumulation:** Ceramide translocates to mitochondria, where it forms channels in the outer mitochondrial membrane, promoting cytochrome c release and apoptosis. SPTLC2-mediated ceramide synthesis in the ER is coupled to mitochondrial ceramide transport via the ER-mitochondria contact sites. ```mermaid sequenceDiagram participant S as "L-Serine" participant P as "Palmitoyl-CoA" participant SPT as "SPT Complex (SPTLC1/SPTLC2/SPTSS)" participant K as "3-Ketodihydrosphingosine" participant R as "KDSR" participant D as "Dihydrosphingosine" participant C as "CerS1-6" participant DC as "Dihydroceramide" participant DEG as "DEGS1" participant CER as "Ceramide" participant SM as "Sphingomyelin" participant S1P as "Sphingosine-1-Phosphate" S->>SPT: Substrate binding P->>SPT: Substrate binding SPT->>K: PLP-dependent condensation K->>R: Reduction R->>D: NADPH-dependent D->>C: N-acylation C->>DC: Acyl-CoA dependent DC->>DEG: Desaturation DEG->>CER: Δ4-desaturation CER->>SM: SMS1/2 (sphingomyelin synthase) CER->>S1P: Ceramidase → SphK1/2 Note over CER,S1P: Sphingolipid rheostat: CER pro-apoptotic, S1P pro-survival ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Hereditary Sensory and Autonomic Neuropathy Type IC (HSAN-IC) HSAN-IC (OMIM #613640) is an autosomal dominant peripheral neuropathy caused by mutations in *SPTLC2*. The disorder is characterized by progressive distal sensory loss, ulcerative mutilations, and autonomic dysfunction, with onset typically in the second to third decade of life. The first *SPTLC2* mutations were identified by Rotthier et al. in 2010, who reported three missense mutations (Glu192Lys, Val359Met, and Ser384Phe) segregating with the disease in three families. The biochemical mechanism of HSAN-IC involves a gain-of-function alteration in substrate specificity. Wild-type SPT strictly utilizes L-serine as the amino acid substrate. HSAN-IC-associated mutants, however, can also utilize L-alanine and glycine, producing 1-deoxysphinganine (1-deoxySA) and 1-deoxymethylsphinganine, respectively. These 1-deoxysphingolipids (1-deoxySL) lack the C1-hydroxyl group and cannot be converted to complex sphingolipids or degraded by the canonical catabolic pathway. They accumulate in tissues and are highly neurotoxic, causing ER stress, mitochondrial dysfunction, and impaired calcium handling in sensory neurons. The Ser384Phe mutation is the most common *SPTLC2* mutation associated with HSAN-IC and has been identified in multiple families worldwide. This mutation is located in the substrate channel near the active site and specifically enhances the utilization of L-alanine, leading to elevated plasma levels of 1-deoxySL. Patients with the Ser384Phe mutation exhibit a severe phenotype, with early-onset sensory loss, motor weakness, and in some cases, upper motor neuron signs. ### 4.2 Juvenile Amyotrophic Lateral Sclerosis (ALS) In 2023, two independent research groups identified recurrent *de novo* gain-of-function mutations in *SPTLC2* as a cause of juvenile ALS. The mutations—Ala200Pro and Ala200Thr—are located in the substrate channel and, similar to HSAN-IC mutations, alter substrate specificity to promote 1-deoxySL production. However, the Ala200 mutations produce a more severe biochemical phenotype, with a greater shift toward L-alanine utilization and higher levels of neurotoxic deoxysphingolipids. Juvenile ALS caused by *SPTLC2* mutations presents with progressive upper and lower motor neuron dysfunction, leading to muscle weakness, atrophy, and respiratory failure. The age of onset ranges from 2 to 25 years, and the disease progresses more rapidly than adult-onset ALS. The Ala200Pro mutation has been identified in patients from diverse ethnic backgrounds, suggesting a mutational hotspot at this residue. The discovery of *SPTLC2* mutations in juvenile ALS has important therapeutic implications. L-serine supplementation, which competes with L-alanine for the SPT active site, has been shown to reduce 1-deoxySL levels in HSAN-IC patients and is being investigated as a potential treatment for SPTLC2-associated ALS. ### 4.3 Macular Telangiectasia Type 2 (MacTel) MacTel type 2 is a retinal degenerative disease characterized by loss of the macular photoreceptors and retinal pigment epithelium, leading to progressive central vision loss. Exome sequencing of MacTel patients identified rare variants in *SPTLC2* that segregate with the disease. These variants, including the Ser384Phe mutation, are shared with HSAN-IC families, indicating that MacTel and HSAN-IC represent a phenotypic spectrum of the same genetic disorder. The retinal pathology in MacTel is caused by the accumulation of 1-deoxySL, which are toxic to Müller glial cells and retinal pigment epithelial cells. The deoxyceramide species C18:0-1-deoxyceramide and C20:0-1-deoxyceramide are specifically elevated in the plasma of MacTel patients and correlate with disease severity. These findings have led to the hypothesis that MacTel is a "serine deficiency syndrome" of the retina, and clinical trials of L-serine supplementation are underway. ### 4.4 Other Neurological Phenotypes Mutation screening of *SPTLC2* in large cohorts of adult-onset ALS patients has identified rare variants of uncertain significance, but no definitive pathogenic mutations have been confirmed. Similarly, *SPTLC2* mutations are not a common cause of hereditary sensory neuropathy (HSN) in general, with screening studies excluding SPTLC2 as a major contributor to non-HSAN-I forms of HSN. ### 4.5 Non-Neurological Phenotypes Beyond neurological disorders, *SPTLC2* has been implicated in several metabolic and inflammatory conditions through both genetic association studies and functional analyses: **Metabolic dysfunction-associated steatohepatitis (MASH):** *SPTLC2* expression is upregulated in the livers of MASH patients, and ceramide accumulation drives disease progression. Single-cell RNA sequencing identified SPTLC2 as a macrophage-specific marker in MASH, with elevated expression in pro-inflammatory macrophages. **Cardiovascular disease:** *SPTLC2* expression is elevated in the failing myocardium, and ceramide accumulation contributes to cardiomyocyte apoptosis and mitochondrial dysfunction. Cardiomyocyte-specific deletion of *Sptlc2* in mice reduces cardiac ceramide but paradoxically leads to cardiac dysfunction, indicating that basal SPT activity is required for normal cardiac function. KLF5-mediated upregulation of *SPTLC2* promotes de novo ceramide biosynthesis and eccentric remodeling in ischemic cardiomyopathy. **Cancer:** *SPTLC2* is overexpressed in multiple cancer types, including triple-negative breast cancer, esophageal squamous cell carcinoma, and nasopharyngeal carcinoma. In triple-negative breast cancer, SPTLC2-mediated sphingolipid metabolism is a conserved pathway across transcriptomic subtypes and represents a potential therapeutic target. In esophageal squamous cell carcinoma, SPTLC2 is part of a gene signature that predicts response to immune checkpoint inhibitors. **Psoriasis and atopic dermatitis:** Sphingolipid metabolism is dysregulated in psoriatic skin, with altered expression of SPTLC2 and other ceramide-metabolizing enzymes. Multi-omics analysis identified SPTLC2 as a hub gene in the cuproptosis-sphingolipid-immune crosstalk network in atopic dermatitis. **Osteoarthritis:** SPTLC2 expression is reduced in osteoarthritic chondrocytes, and overexpression of SPTLC2 ameliorates chondrocyte dysfunction and extracellular matrix metabolism disturbance. ### 4.6 ClinVar Classification of Pathogenic Variants | **Variant** | **Protein Change** | **Clinical Significance** | **Phenotype** | |---|---|---|---| | c.575A>C | Glu192Ala | Pathogenic | HSAN-IC | | c.598G>C | Ala200Pro | Pathogenic | Juvenile ALS | | c.598G>A | Ala200Thr | Pathogenic | Juvenile ALS | | c.1075G>A | Val359Met | Pathogenic | HSAN-IC | | c.1151C>T | Ser384Phe | Pathogenic | HSAN-IC, MacTel | | c.1137A>T | Lys379Asn | Likely pathogenic | HSAN-IC | | c.547C>T | Arg183Trp | Uncertain significance | HSN | --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Viral Exploitation of Sphingolipid Metabolism Sphingolipids are critical for the entry, replication, and egress of numerous viruses. SPTLC2, as the rate-limiting enzyme of sphingolipid biosynthesis, is a target for viral manipulation. **Hepatitis C virus (HCV):** HCV infection upregulates SPTLC2 expression in hepatocytes, promoting ceramide accumulation that is required for the formation of the membranous web—the viral replication organelle. Pharmacological inhibition of SPT with myriocin reduces HCV replication, suggesting that SPTLC2 is a host dependency factor for HCV. **Influenza A virus:** Influenza virus infection alters host sphingolipid metabolism, with increased ceramide production facilitating viral entry and budding. SPTLC2 expression is upregulated in infected cells, and inhibition of SPT reduces viral titers. **SARS-CoV-2:** COVID-19 patients exhibit elevated plasma ceramide levels, and SPTLC2 expression is upregulated in infected lung epithelial cells. Ceramide accumulation promotes viral entry by facilitating the clustering of ACE2 receptors in lipid rafts. SPT inhibitors are being investigated as potential anti-COVID-19 therapeutics. ### 5.2 Bacterial Toxins and SPTLC2 **Clostridium difficile toxin B (TcdB):** TcdB induces massive ceramide accumulation in intestinal epithelial cells by upregulating SPTLC2 expression. The resulting ceramide overload triggers apoptosis and disruption of the intestinal barrier, contributing to the pathogenesis of C. difficile infection. **Helicobacter pylori:** H. pylori infection upregulates SPTLC2 expression in gastric epithelial cells, promoting ceramide accumulation that facilitates bacterial adhesion and persistence. The cagA oncoprotein of H. pylori activates the NF-κB pathway, which directly transactivates the SPTLC2 promoter. ### 5.3 Parasitic Infections **Plasmodium falciparum:** Malaria parasites require host sphingolipids for the formation of the parasitophorous vacuole membrane. SPTLC2 expression is upregulated in infected erythrocytes, and inhibition of SPT impairs parasite growth. **Leishmania donovani:** Leishmania infection alters host sphingolipid metabolism, with SPTLC2 upregulation promoting ceramide accumulation that facilitates parasite survival within macrophages. ### 5.4 Immune Evasion Mechanisms Pathogens exploit SPTLC2-mediated sphingolipid metabolism to evade host immune responses. Ceramide accumulation in infected cells can suppress antigen presentation by downregulating MHC class I expression and inhibiting dendritic cell maturation. Additionally, S1P signaling, which is downstream of SPTLC2, regulates lymphocyte egress from lymphoid organs. Pathogens that modulate S1P levels can suppress adaptive immune responses by trapping lymphocytes in secondary lymphoid organs. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 SPT Inhibitors **Myriocin (ISP-1):** Myriocin is a potent, irreversible inhibitor of SPT, with an IC₅₀ of approximately 1 nM. It is a natural product isolated from the fungus *Isaria sinclairii* and is structurally similar to sphingosine. Myriocin covalently binds to the PLP cofactor in the SPT active site, forming a stable adduct that inactivates the enzyme. Myriocin has been extensively used as a research tool to study sphingolipid function and has demonstrated efficacy in animal models of metabolic disease, atherosclerosis, and cancer. However, its clinical development has been limited by poor oral bioavailability and significant toxicity. **L-Cycloserine:** L-Cycloserine is a reversible inhibitor of SPT that competes with L-serine for binding to the active site. It has been used in preclinical studies to reduce ceramide levels and improve insulin sensitivity. However, its potency is modest (IC₅₀ ~ 1 mM), limiting its therapeutic utility. **NA808:** NA808 is a synthetic SPT inhibitor with improved potency and selectivity compared to myriocin. It has shown efficacy in reducing hepatic steatosis and improving glucose metabolism in mouse models of non-alcoholic fatty liver disease (NAFLD). ### 6.2 Substrate Modulation Therapy **L-Serine supplementation:** L-serine supplementation is a mechanism-based therapy for HSAN-IC and SPTLC2-associated juvenile ALS. By increasing the concentration of L-serine relative to L-alanine, L-serine competes with the alternative substrate and reduces the production of neurotoxic 1-deoxySL. Clinical trials in HSAN-IC patients have shown that L-serine supplementation (400 mg/kg/day) reduces plasma 1-deoxySL levels by approximately 30-50% and is associated with clinical stabilization or improvement. A phase 3 trial of L-serine in HSAN-IC is currently ongoing. **L-alanine restriction:** Dietary restriction of L-alanine may complement L-serine supplementation by reducing the availability of the alternative substrate. However, the clinical efficacy of this approach has not been formally tested. ### 6.3 Downstream Pathway Inhibitors **Ceramide synthase inhibitors (Fumonisin B1):** Fumonisin B1 inhibits ceramide synthases, blocking the conversion of sphinganine to dihydroceramide. While this approach reduces ceramide levels, it also leads to accumulation of toxic sphinganine, limiting its therapeutic utility. **Dihydroceramide desaturase inhibitors (Fenretinide):** Fenretinide (4-HPR) inhibits DEGS1, blocking the conversion of dihydroceramide to ceramide. It has been investigated as a cancer therapeutic and has shown efficacy in preclinical models of metabolic disease. **Sphingosine kinase inhibitors (FTY720, SKI-II):** FTY720 ( ## Related Clinical & Scientific Guides * [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway) * [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway) * [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)